Innovent Biologics Launches Phase 1 Trial for New Gout Treatment IBI3011 Innovent Biologics has successfully dosed the first participant in a Phase 1 clinical trial for IBI3011, targeting gout treatment. This monoclonal antibody aims to revolutionize care for patients suffering from gout flares.

Innovent Biologics Launches Phase 1 Trial for New Gout Treatment IBI3011 #China #Suzhou #Innovent_Biologics #Gout_Treatment #IBI3011

Innovent Unveils Groundbreaking Research at 2025 ACR Annual Meeting Innovent Biologics showcases groundbreaking study results for innovative therapies targeting various inflammatory diseases at ACR 2025.

Innovent Unveils Groundbreaking Research at 2025 ACR Annual Meeting #China #Suzhou #Innovent_Biologics #IBI3011 #IBI3034